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ABSTRACT
Objective To measure the clinical and immunological
outcomes of HIV positive adult patients receiving
combination antiretroviral therapy in conflict affected
northern Uganda.
Design Prospective cohort study.
Setting Gulu District, northern Uganda.
Participants 1625 adults (aged over 14 years) receiving
combination antiretroviral therapy.
Main outcome measures Primary outcome: all cause
mortality.Secondaryoutcomes:impactofcovariates(sex,
age, CD4 count at start, adherence, tuberculosis at start,
duration of treatment, and internally displaced person
status) on mortality.
Results Sixty nine (4.2%) patients died during follow-up.
The mortality incidence rate was 3.48 (95% confidence
interval 2.66 to 4.31) per 100 person years. Patients
started treatment with a median CD4 count of 157
(interquartile range 90-220) cells/μl; most (1009; 63%)
had World Health Organization stage 2 defined illness.
Sixtytwopatientshadpulmonarytuberculosisatthestart
of treatment. Of the 1521 patients with adherence data,
118 (7.8%) had adherence of less than 95% and 1403
(92.2%) had adherence of 95% or above.
Conclusion Patients receiving combination antiretroviral
therapy in conflict affected northern Uganda had a
mortality comparable to that of patients in peaceful, low
income settings and better adherence than patients in
higher income settings. These favourable findings
highlight the need to expand access to combination
antiretroviral therapy in populations affected by armed
conflict.
INTRODUCTION
Sub-Saharan Africa is home to two thirds of the global
HIV/AIDS epidemic.
1 The continent simultaneously
has the world’s highest rate of armed conflict, which
affects more than a third of African countries.
2 Inter-
national policy guidelines for humanitarian responses
previouslyintimatedthattheprovisionofcombination
antiretroviral therapy was not feasible in complex
emergencies,
34owing to associated population move-
ments and poor access to basic health services.
5 As a
consequence,populationsaffectedbyconflictcontinue
to have very limited access to combination anti-
retroviral therapy.
1
A recent consensus statement from many inter-
national agencies, including the World Health Orga-
nization and the United Nations High Commissioner
for Refugees (UNHCR), indicated that provision of
combination antiretroviral therapy to HIV infected
peopleinemergencysettingsrepresentsapublichealth
andhumanrightsimperative.
67TheUNHCRhassince
developed clinical and operational guidelines for the
management of combination antiretroviral therapy in
displaced populations.
8 The feasibility of distributing
such therapy in complex humanitarian settings has
been previously evaluated in the Eastern Democratic
RepublicofCongo.
9Acriticalneedexistsforincreased
research in this area to inform evidence based
humanitarian interventions.
10 We present clinical and
immunological outcomes of a large cohort of adult
patients receiving combination antiretroviral therapy
in an ongoing complex humanitarian emergency.
METHODS
Setting
Northern Uganda has been in a state of humanitarian
emergency for more than 20 years, in what has been
called one of Africa’s longest standing armed conflicts
and a neglected humanitarian emergency. Of the
estimated 1.6 million people displaced in northern
Uganda between 2002 and 2004, most continue to
reside in protected camps.
11 Over the past year,
security in the region has been characterised by brief
but violent attacks by the Lord’s Resistance Army and
neighbouring cattle rustling tribes,varying in intensity
and geographic focus. As of June 2008, efforts towards
peace were compromised and movement restrictions
remain in place for those living in internally displaced
persons’ camps.
Between January and July 2005, Gulu district and
municipality had a population of approximately
566000 inhabitants. Most residents lived in internally
displaced persons’ camps. The crude mortality rate in
the area was estimated to be high, reaching 1.22 (95%
confidence interval 1.00 to 1.44) per 10000 per day
among camp residents and 1.29 (1.04 to 1.53) per
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ratesexceedtheemergencythresholdof1.0per10000
perday.
12Inthisperiod,violencewasaleadingcauseof
death in Gulu District, representing approximately
11% of all deaths. The overall violence specific
mortality in Gulu District was approximately 0.17
(0.12 to 0.21) people per 10000 per day.
10 Tenuous
peace has been present since the last major fighting in
December 2004. However, most Gulu residents have
chosen not to leave the camp for fear of resurgent
violence. The outskirts of Gulu municipality have
experienced more recent violence.
St Mary’s Lacor Hospital, a large non-governmental
hospital in Gulu, reports HIV/AIDS as the most
c o m m o nr e a s o nf o rd e a t hi n2 0 0 5 .
13 A sero-surveillance
study among women attending antenatal clinics in Gulu
District in 2006 found a prevalence of HIV infection of
10.3%. Women living in communities surrounding
internally displaced persons’ camps had a higher
prevalence of HIV infection than did those living in the
camps (11.6% v 6.3%), indicating that these camps may
have had a protective effect on transmission of HIV in
Gulu.
14 Prevention of mother to child transmission
programmes in northern Uganda indicate that the
prevalence of HIV infection may be lower in rural
areas.
15 A geographic information system assessment of
HIV/AIDS health services in northern Uganda in 2007
found that Gulu District had 14 HIV voluntary counsel-
ling and testing sites, five clinics for the prevention of
mother to child transmission, and six sites providing
combination antiretroviral therapy to eligible patients.
Most of these health services are located in the (urban)
municipality.
16
Programme
The AIDS Support Organization (TASO) began
providingHIV/AIDSservicesinGuluin2004.Before
this, no combination antiretroviral therapy was pro-
vided publicly and private provision of care was
limited. Since 2004, TASO has started combination
antiretroviraltherapyin1625adultsand57childrenin
this setting, becoming the largest provider in the
region. Patients initially received combination anti-
retroviral therapy at the TASO clinic in Gulu. In 2005
TASO began a home based treatment programme for
patientswhoneedhomebasedcareoroutreachinrural
areas of Gulu District and camps. The primary
initiation regimen is based on non-nucleoside reverse
transcriptase inhibitors. At the time of data collection
first line treatment typically comprised nevirapine,
lamivudine, and stavudine, and second line treatment
comprised boosted lopinavir, didanosine, and zidovu-
dine. Criteria used for starting treatment when these
data were gathered included WHO stage 3 or 4 illness
or a CD4 cell count below 200 cells/μl. HIV-1 RNA
concentrations are not used in this setting, as no
facilitiestomeasureviralloadexistintheregion.Given
the infrastructure constraints and pressing clinical
needs, many patients will start combination anti-
retroviral therapy on clinical presentation and may
not have CD4 evaluations.
Apart from patients receiving services at the main
TASO clinic in Gulu town, outreach programmes to
the internally displaced persons’ camps in Pabbo,
Bobbi,andAwachalsoexist.Themobilecombination
antiretroviraltherapyclinicstakeplaceeveryfortnight
in the camps, and patients schedule appointments to
meet with field workers and clinicians. Mobile clinics
take place in public settings, as well as in individual
households in the camps. Field workers manage drug
distribution, and clinicians provide clinical care. Field
officers who document and report outcomes to the
combinationantiretroviral therapy team leaders in the
camps or camp elders manage side effects and
adherence.Inanticipationofanyrebelattacks,patients
are given a hotline mobile number; patients who need
combination antiretroviral therapy or have clinical
problems are escorted by military transport to the
nearest safe TASO clinic or receive military intelli-
genceofsaferoutes.Stigmaremainsamajorreasonfor
not using voluntary counselling and testing.
Data collection
Clinicians and field workers complete standardised
forms detailing patients’ demographics, as well as
clinical, psychosocial, and drug use data at each visit.
Thesedataarethenhandentered,induplicate,intothe
TASO database. Patients are given a unique confiden-
tial identifying number.
Demographic, clinical, and immunological characteristics of patients (n=1625). Values are
numbers (percentages) unless stated otherwise
Characteristic Overall (n=1625) Women (n=1162) Men (n=463)
Median (IQR) age (years) 39 (33-46) 38 (33-45) 41 (36-47)
Internally displaced persons’
camp resident:
Yes 227 (14.0) 157 (13.5) 70 (15.1)
No 1398 (86.0) 1005 (86.5) 393 (84.9)
WHO stage at start: (n=1591) (n=1140) (n=451)
1 13 (0.8) 10 (0.9) 3 (0.7)
2 1009 (63.4) 749 (65.7) 260 (57.7)
3 482 (30.3) 322 (28.3) 160 (35.5)
4 87 (5.5) 59 (5.2) 28 (6.2)
Tuberculosis at start: (n=1623) (n=1160)
Yes 62 (3.8) 32 (2.8) 30 (6.5)
No 1561 (96.2) 1128 (97.2) 433 (93.5)
Adherence: (n=1521) (n=1094) (n=427)
<95% 118 (7.8) 80 (7.3) 38 (8.9)
≥95% 1403 (92.2) 1014 (92.7) 389 (91.1)
Died:
Yes 69 (4.3) 45 (3.9) 24 (5.2)
No 1556 (95.8) 1117 (96.1) 439 (94.8)
CD4 cell count (n=982) (n=704) (n=278)
>200/μla ts t a r t :
Yes 318 (32.4) 247 (35.1) 71 (25.5)
No 664 (67.6) 457 (64.9) 207 (74.5)
Median (IQR) at start 157 (90-220) 166 (99-232) 143 (80-201)
Median (IQR) change 0 (0-0) 0 (0-0) 0 (0-0)
IQR=interquartile range.
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motorcycles is responsible for active retention and
follow-up of patients. The field adherence monitoring
teamvisitspatientswhofailtoattendanyappointment
and those who have requested home based care. The
team consists of medical attendants who do adherence
counselling and clinical observation and provide
combination antiretroviral therapy. TASO has a
rigorous method for measuring adherence, which far
surpasses most Western standards. It involves a
composite of pharmacy monitored drug possession
ratio, pharmacy refill records, and a three day recall
report by patients or care givers. TASO defines
adequate clinical adherence to combination anti-
retroviral therapy as ≥95%.
Patients began receiving combination antiretroviral
therapy from 8 June 2005 and were followed until 29
January 2008. The median numbers of patients who
entered the programme were 47 (interquartile range
23-72) monthly, 129 (54-221) every three months, and
287 (49-358) every six months.
Outcomes
The primary outcome of interest was all cause
mortality. Secondary outcomes analyses included
assessment of immunological status at start of combi-
nation antiretroviral therapy and patients’ character-
istics.Covariatesinouranalysisincludedage,sex,CD4
count at start of treatment, presence of tuberculosis,
internally displaced person status, and adherence
defined as above.
Analysis
WeusedKaplan-Meiermethodstoassesssurvivalover
time. We used Cox proportional hazardsto determine
ifcovariatesdeterminedinadvanceaffectedmortality.
Our covariates included sex, age, CD4 count at start
(≤200 v >200 cells/μl), adherence, duration of treat-
ment, tuberculosis at start, and internally displaced
person status. We explored the effect of missing CD4
counts at baseline on the relation between adherence
andmortalityinsensitivityanalyses.Thefinaladjusted
model used a backward selection process based on the
Akaikeinformationcriterion.Wecheckedthe propor-
tionalhazardsassumptionforthismodelbyusingatest
basedontheweightedresidualsandfoundnoevidence
of deviation from this assumption. We used the
Hosmer-Lemeshow test to test the final model for fit
and found no evidence of a lack of fit. We additionally
examined whether CD4 count at the start of treatment
was affected by sex, internally displaced person status,
or the presence of tuberculosis. We formally tested
these by using the χ
2 test and Fisher’s exact test. All P
values are exact. All tests of significance are two sided,
and P<0.05 indicates that an association is statistically
significant. We used SAS (version 9.0) for all calcula-
tions.
RESULTS
The table describes the demographic, clinical, and
immunological characteristics of patients included in
theanalysis.Of5625adults(aged>14years)receiving
clinical care from TASO in Gulu District, a total of
1625 are receiving combination antiretroviral therapy
andwereincludedinouranalysis—100%ofallpatients
who ever received combination antiretroviral therapy
fromTASOinGuluDistrict.Thecohortrepresenteda
cumulative1981patientyearsoffollow-up.Most(72%)
patients were women, and the median age was 39
(interquartile range 33-46) years. Of all internally
displaced people in the study, 14.0% resided in official
government camps and the rest resided in outlying
areas. All patients were started on non-nucleoside
reverse transcriptase inhibitor based regimens.
Patients started treatment with a median CD4 count
of 157 (interquartile range 90-220) cells/μl, and most
(63%) had WHO stage 2 disease. A total of 62 patients
hadbeen diagnosedashavingpulmonarytuberculosis
at baseline. The median follow-up time was 12.8 (7.7-
23.1)months;69(4.2%)patientsdiedduringfollow-up,
g i v i n gam o r t a l i t yi n c i d e n c er a t eo f3 . 4 8( 9 5 %
confidence interval 2.66 to 4.31) per 100 person years.
Of the 982 patients with available baseline CD4
counts, 664 (68%) had CD4 counts of 200 cells/μlo r
less. Median follow-up was similar by baseline CD4
count: 10.5 (interquartile range 6.3-15.0) months for
patients with CD4 counts 200 cells/μl or less and 14.4
(9.3-27.5)monthsforthosewithCD4countsabove200
cells/μl. Mortality varied by baseline CD4 cell count:
21/664 (3.2%, 3.22/100 patient years) patients with
CD4 counts of 200 cells/μl or less died compared with
3/316(0.9%,0.68/100patientyears)patientswithCD4
counts above200 cells/μl. Forthe 643 patientswithno
initialCD4countavailable,themedianfollow-uptime
was 14.3 (9.1-26.1) monthsand 45 patients died(7.0%,
50.8/100 person years). Patients without CD4 counts
were less likely to be in a camp and were less likely to
have tuberculosis at the start of treatment than were
patients who had CD4 cell counts available (internally
displaced persons’ camp: 69/643 (10.7%) v 158/982
(16.1%), P=0.002; tuberculosis: 5/643 (0.8%) v 57/980
Time to death (months)
S
u
r
v
i
v
a
l
 
p
r
o
b
a
b
i
l
i
t
y
0 2
No of patients at risk:
CD4 <200
CD4 >200
No CD4 count
available
4 6 8 10 12
Median follow-up
14 16 18 20 22 24 26 28
643 588 506 414 276 258 207 86
318 285 251 188 133 131 104 64
664 570 448 281 109 99 53 32
0.90
0.92
0.94
Overall log rank P value: <0.01
Log rank P value comparing CD4 <200 v CD4 >200: 0.03
0.96
0.98
1.00
CD4 <200
CD4 >200
No CD4 count
available
Fig 1 | Kaplan-Meier plot for survival in patients with CD4 cell count at start of treatment >200
cells/μlo r≤200 cells/μl and in those with no CD4 data available
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betweenpatientswithoutorwithcellcountsintermsof
sex:458/643(71.2%)v704/982(71.7%)(P=0.8).Figure
1 shows the Kaplan-Meier plot for survival in patients
withCD4countsof200cells/μlorlowerandabove200
cells/μl and for those without CD4 cell evaluations.
Themedianfollow-uptimeforthe1521patientswho
had complete adherence data was 13.7 (8.4-23.6)
months. Of the 1521 patients with complete data for
adherence, 118 (7.8%) patients had adherence below
95%and1403(92.2%)hadadherenceof95%orabove.
Themedianfollow-upwas26.0 (14.4-28.4) monthsfor
patientswithadherencebelow95%and12.8(8.1-22.4)
months for those with adherence of 95% or above. A
total of 11/118 (9.3%, 5.24/100 patient years) patients
with less than 95% adherence died compared with
17/1403(1.2%,1.00/100patientyears)patientswithat
least95%adherence.Figure2showstheKaplan-Meier
plot for survival of patients defined as adherent or not
adherent (<95% or ≥95%).
Of the 69 people who died, the shortest time
between the start of treatment and death was eight
days. Of the deaths, 17 (25%) occurred within 1.
3 months of starting treatment, 35 (50%) within 2.
5monthsofstartingtreatment,and52(75%)within5.
1 months of starting treatment. No violent deaths
occurred in this cohort.
Lower mortality was associated with female sex
(hazard ratio 0.70, 95% confidence interval 0.55 to 0.91,
P=0.02),higherbaselineCD4count(hazardratioper100
cell increase 0.14, 0.06 to 0.34, P<0.0001), and at least
95% adherence (hazard ratio 0.14, 0.10 to 0.21,
P<0.0001). Residence in a camp (0.39, 0.14 to 1.05,
P=0.06)andage(hazardratioperyearincrease1.00,0.99
to 1.02) were not associated with mortality outcomes.
Female sex was associated with higher CD4 cells
countsatbaseline(oddsratio1.56,1.15to2.13,P=0.005).
Presence of tuberculosis at baseline was associated with
lowerCD4counts(0.49,0.25to0.95,P=0.04).Residence
in a camp was not associated with CD4 counts at start of
treatment (0.84, 0.58 to 1.22, P=0.34).
DISCUSSION
Our study represents the first effort to assess outcomes
oftreatmentamongalargecohortofpatientsreceiving
combination antiretroviral therapy in a complex
emergency setting. Adults receiving such treatment in
Gulu, northern Uganda, showed clinical outcomes
betterthanthosefoundintheonlyotherexistingstudy
of patients receiving combination antiretroviral ther-
apy in a conflict setting.
9 The results compare
favourably with those found in peaceful regions of
Uganda and other low income countries.
17-20 The high
median age (39, interquartile range 33-46, years) of
patients clinically eligible for and receiving combina-
tion antiretroviral therapy suggests that many people
are infected with HIV in their late 20s. The predomi-
n a n c eo fw o m e n( 7 2 % )i no u rc o h o r tm i g h tb e
explained by the comparatively low number of men
in Gulu District.
12 These findings are consistent with
UNAIDSestimatesofagespecificHIVprevalenceand
access to combination antiretroviral therapy in
Uganda.
1
Findings in context with other studies
The mortality incidence rate among adult patients
receiving combination antiretroviral therapy in our
cohort—3.48(95%confidenceinterval2.66to4.31)per
100 person years—was about half of that found in
Bukavu, Democratic Republic of Congo (7.9 (3.6 to
12.1) per 100 person years), a setting with ongoing
active violence and noticeably fewer aid agencies
available.
9 Interestingly, this is also lower than the
mortality found in better resourced, politically stable
areasofUganda,suchasRakai,wherethemortalityhas
been5.2per100personyearsamongpatientsreceiving
combination antiretroviral therapy.
17 We found that
residence in a camp did not predict worse outcomes
thanurbandwelling.ThisisconsistentwithWHOand
Ugandangovernmentreportsaboutcrudemortalityin
Gulu District,
12 and it supports the view that commu-
nitiessurroundinginternallydisplacedpersons’camps
maybemorevulnerablethanpopulationslivingwithin
them.
21
Strengths and limitations
Severalstrengthsandlimitationsneedtobeconsidered
in interpreting our study. Strengths include the
retention of patients in our cohort. Whereas many
programmesinAfricaareaffectedbyconsiderableloss
to follow-up,
22 our programme uses a special counsel-
lingteamonmotorcyclestoconsistentlytrackpatients.
This model is now being implemented by other
organisations throughout Africa. Our adherence
counsellingissuperiortothatfoundinmoredeveloped
settings,asTASOhasspecificallyemployedadherence
counsellorsanddatabasemanagersateachTASOsite.
Regarding limitations, this is a prospective cohort.
As with any cohort study, confounding variables of
whichweareunawaremaybepresent.Wehavetriedto
control for these by using a priori explanations of bias.
We did not have routine CD4 counts for all patients,
which is common in emergency humanitarian settings
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Fig 2 | Kaplan-Meier plot for survival in patients defined as adherent or not adherent (<95% or
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constraints, we do not do viral load evaluations. We
use clinical signs and treatment interruptions, which
have been shown to be possibly equally effective for
monitoring patients’ outcomes.
1923
In clinical monitoring, mortality provides the
strongest inference of treatment successes. We did a
sensitivity analysis in which the Cox proportional
hazards survival analysis was re-done with adjustment
for all variables except CD4 at start of treatment. This
increased the sample size from 947 to 1519, and we
found the same magnitude of association between
adherenceandmortalityasinthepreviousanalysisthat
excluded patients without CD4 counts. Indeed, this is
common circumstance in many resource poor
settings.
24
Possible explanations of findings
Our finding that only 14% of patients receiving
combination antiretroviral therapy resided in inter-
nally displaced persons’ camps may reflect a bias
specifically in access to HIV treatment. Internally
displaced people residing in camps often provide
protection and support to their neighbours. Among
patients residing outside camps, we were unable to
differentiate those forcibly displaced by conflict from
those who voluntarily migrated to Gulu District for
other reasons. The reality remains that all of Gulu
District and Municipality’s population has been
affected by armed conflict.
The adherence to treatment among our cohort of
adult patients receiving combination antiretroviral
therapy was high. This compares favourably with
levels of adherence reported from studies involving
patients in well resourced, politically stable areas of
Uganda or the rest of the world. Whereas 92% of our
patients had at least 95% adherence, the reported
adherence in the capital, Kampala, is 82%.
1819 The
adherence among our patients in Gulu is particularly
striking when compared with pooled adherence rates
across sub-Saharan Africa and North America, where
77% and 55% of patients adhered to combination
antiretroviral therapy.
25 Duration of clinical follow-up
may contribute to adherence, as the median follow-up
time for patients with good adherence was 12.
8months,comparedwith26.0monthsamongpatients
with poor adherence.
Implications
T h e s ei m p r e s s i v ec l i n i c a lo u t c o m e sm a yl a r g e l yb e
possible owing to the stability of the population in Gulu
after the influxes of 2002 and 2004.
11 Compared with
other districts affected by conflict in northern Uganda,
Gulu has the largest number of health facilities and thus
betteraccessforinternallydisplacedpeopleandresident
communities.
16 Maintaining positive clinical outcomes
among patients receiving combination antiretroviral
therapy may be challenging in the face of anticipated
movements of population. In 2008 optimistic inter-
national organisations expected that 35% of internally
displaced people in northern Uganda would relocate
“home,”45%wouldbeintransit,and20%wouldremain
in camps.
26 In early June 2008, the optimistic peace
process between the Lord’s Resistance Army and the
government broke down. Steps will need to be taken to
ensure that combination antiretroviral therapy is not
disruptedasa resultofthe relocationofpeople fromthe
camp to their homes and vice versa.
827 This should
include cooperation with HIV treatment facilities in
neighbouring districts and delivery of additional emer-
gency “relocation” stock of combination antiretroviral
therapy and the creation of treatment information cards
and duplicate medical records for patients.
9
Unanswered questions and future research
Humanitarianandgovernmentagenciesshouldusethe
anticipated repatriation of internally displaced people
as an opportunity to investigate different modalities of
combination antiretroviral therapy programmes for
displaced and returning populations. Research in this
area would facilitate the development of international
best practices for sustaining drug distribution, for the
monitoring of clinical and viral outcomes, and for the
management of adverse outcomes and opportunistic
infections among displaced and returning patients.
8
Development of programmes and policies in this area
isparticularlyimportantinlightofthefactthat330000
refugees and 33000 internally displaced people
returned home in 2005.
28 Identifying programmatic
strategies for maintaining access to combination anti-
retroviral therapy during movements of populations
would also be applicable to newly displaced popula-
tions. The need for development of policies and
programmes in this area is highlighted by situations
such as Zimbabwe’s 2005 forced displacement of
700000 urban residents, including 79500 HIV posi-
tive adults and children, during the Operation
Murambatswina
29; and by continued arrivals of
refugees from sub-Saharan African countries such as
Kenya, Sudan, the Democratic Republic of Congo,
Somalia, Cote D’Ivoire, Burundi, and Liberia.
28
Conclusions
Our study describes the first outcomes among a large
cohortofpatientsreceivingcombinationantiretroviral
therapy in northern Uganda. Our findings show that
theprovisionofsuchtreatmentincontextswitharmed
conflict is both feasible and potentially highly success-
ful. Our study validates recent policies set out by the
WHAT IS ALREADY KNOWN ON THIS TOPIC
Early guidelinessuggestedthatantiretroviraltherapy forpopulationsaffectedbyconflictwas
untenable
Access to antiretroviral therapy for conflict affected populations remains low
WHAT THIS STUDY ADDS
Patientsreceivingantiretroviraltherapy hadfavourableoutcomesinmortalityandadherence
Innovativestrategiestoretainpatientsincaremaycontributetopositivehealthoutcomesand
reduce mortality and loss to follow-up
Expansion of antiretroviral care to other conflict affected populations is warranted
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emergencies and shows the imperative of expanding
accesstocombinationantiretroviraltherapytopopula-
tions affected by armed conflict.
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